84400-99-7

Basic information

• Product Name: 7-CHLOROFURO[2,3-C]PYRIDINE
• Synonyms: 7-CHLOROFURO[2,3-C]PYRIDINE
• CAS NO: 84400-99-7
• Molecular Formula: C₇H₄ClNO
• Molecular Weight: 153.57
• Mol File: 84400-99-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 64-65.5 °C
• Boiling Point: 242.806 °C at 760 mmHg
• Flash Point: 100.646 °C
• Appearance: /
• Density: 1.377 g/cm³
• Vapor Pressure: 0.052mmHg at 25°C
• Refractive Index: 1.624
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.88±0.30(Predicted)
• CAS DataBase Reference: 7-CHLOROFURO[2,3-C]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-CHLOROFURO[2,3-C]PYRIDINE(84400-99-7)
• EPA Substance Registry System: 7-CHLOROFURO[2,3-C]PYRIDINE(84400-99-7)

Safety Data

• Hazardous Substances Data: 84400-99-7(Hazardous Substances Data)

Usage

General Description

7-Chlorofuro[2,3-c]pyridine, also known as 7-chloro-2,3-dihydro-6H-furo[2,3-c]pyridine, is a chemical compound with the molecular formula C6H4ClNO. It is a heterocyclic compound that belongs to the furo[2,3-c]pyridine family. This chemical features a chlorine atom attached to a furo[2,3-c]pyridine ring, making it a halogenated furo[2,3-c]pyridine derivative. It has potential applications in the development of pharmaceuticals and agrochemicals due to its unique structural properties. Additionally, it may also be used as an intermediate in organic synthesis for the preparation of other heterocyclic compounds. As with any chemical compound, proper handling and safety precautions should be observed when working with 7-chlorofuro[2,3-c]pyridine.

InChI:InChI=1/C7H4ClNO/c8-7-6-5(1-3-9-7)2-4-10-6/h1-4H

Upstream product

• 84400-98-6 furo<2,3-c>pyridin-7(6H)-one 
• 181526-20-5 Furo[2,3-c]pyridine 6-oxide 
• 1219102-03-0 7-chloro-2-trimethylsilylfuro[2,3-c]pyridine 
• 19539-50-5 furo<2,3-c>pyridine 
• 119924-26-4 (E)-3-(2-furanyl)-2-propenoyl azide 
• 26956-43-4 5H-furo[3,2-c]pyridin-4-one 
• 539-47-9 3-(fur-2-yl)crotonic acid 
• 39244-10-5 (E)-3-furan-3-yl-acrylic acid 
• 1066-54-2 trimethylsilylacetylene 

Downstream Products

• 19539-50-5 furo<2,3-c>pyridine 
• 117612-53-0 7-methoxyfuro[2,3-c]pyridine 
• 86518-10-7 acetyl-2 chloro-4 furo<3,2-c>pyridine 
• 153863-91-3 2-aminomethylfuro<2,3-c>pyridine 
• 112372-06-2 furo<2,3-c>pyridine-2-carboxaldehyde 
• 1613479-45-0 C₁₃H₇F₂NO₂ 
• 1326714-73-1 tert-butyl 4-(4-{7-amino-2-[3,5-bis(trifluoromethyl)phenyl]furo[2,3-c]pyridin-4-yl}-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1326714-72-0 2-{3,5-bistrifluoromethylphenyl}-4-bromofuro[2,3-c]pyridin-7-ylamine 
• 1326714-71-9 2-{(3,5-bistrifluoromethyl)phenyl}furo[2,3-c]pyridin-7-ylamine 
• 1326714-70-8 2-{3,5-bis(trifluoromethyl)phenyl}-7-chlorofuro[2,3-c]pyridine 
• 1326714-64-0 4-iodofuro[2,3-c]pyridin-7-ylamine 
• 1140240-20-5 furo[2,3-c]pyridine-7-ylamine 

Relevant articles and documents

HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.

7-AMINOFUROPYRIDINE DERIVATIVES

Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.